Oral semaglutide: the innovation in type 2 diabetes management
Oral semaglutide is the first-in-class glucagon-like peptide-1 receptor agonist available in the form of pills administered per os. PIONEER — the clinical trial program assessing the efficacy and safety of oral semaglutide — demonstrated the dose-dependent efficacy of the drug: the reduction of up...
Saved in:
| Main Authors: | M. V. Shestakova, M. Sh. Shamkhalova, G. R. Galstyan, L. A. Ruyatkina, L. A. Suplotova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2021-09-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12790 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials
by: M. Sh. Shamkhalova, et al.
Published: (2022-07-01) -
Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data
by: Sandeep Gudibanda, et al.
Published: (2024-10-01) -
Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
by: Noha Hafeez, et al.
Published: (2024-12-01) -
Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan
by: Mohamed Hassanein, et al.
Published: (2022-12-01) -
Oral semaglutide for the treatment of obesity: a retrospective real-world study
by: Mitja Krajnc, et al.
Published: (2025-05-01)